Search

Ocular Therapeutix Inc

Cerrado

SectorSanidad

9.99 -1.19

Resumen

Variación precio

24h

Actual

Mínimo

9.88

Máximo

10.08

Métricas clave

By Trading Economics

Ingresos

9.8M

-79M

Ventas

2.7M

13M

BPA

-0.35

Margen de beneficios

-584.512

Empleados

325

EBITDA

10M

-74M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+152.75% upside

Dividendos

By Acuity

Próximas Ganancias

3 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

462M

2.4B

Apertura anterior

11.18

Cierre anterior

9.99

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

320 / 339 Clasificación en Healthcare

Ocular Therapeutix Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 sept 2026, 23:25 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, rising from a low post-close and currently above Friday's close but below its 20-day moving average.

17 sept 2026, 20:07 UTC

Ocular Therapeutix Inc is advancing, maintaining gains from Wednesday, despite earlier pulling back from a session high while remaining below its 20-day moving average.

16 sept 2026, 20:10 UTC

Event
Social Media

Ocular Therapeutix Inc shares fell sharply despite positive social media sentiment about its NDA filing for Axpaxli and recent FDA discussions.

15 sept 2026, 22:02 UTC

Event

Ocular Therapeutix Inc. plans to submit its New Drug Application by Q4 2026, but shares are lower in after-market hours amid broader economic concerns.

14 sept 2026, 19:17 UTC

Ocular Therapeutix Inc is trading higher during Monday's session, having gained since Friday's close, despite a negative broader market sentiment.

11 sept 2026, 23:51 UTC

Ocular Therapeutix Inc shares are higher in after-market hours, supported by improved fiscal management reflected in a narrower-than-expected budget deficit of $167 billion for August.

10 sept 2026, 22:26 UTC

Ocular Therapeutix Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The stock retraced from an initial rise.

9 sept 2026, 23:36 UTC

Ocular Therapeutix shares are lower in after-market trading, continuing a decline since Wednesday's close, despite remaining near the upper end of their one-month range.

8 sept 2026, 20:02 UTC

Ocular Therapeutix Inc shares are higher during Tuesday's market hours, despite earlier pulling back from a session high. No specific news was identified.

3 sept 2026, 20:01 UTC

Ocular Therapeutix Inc's shares are lower today, breaking a trend of higher closes since Wednesday. No specific news was identified to explain the decline.

2 sept 2026, 23:31 UTC

Ocular Therapeutix shares were roughly flat in after-market hours. The broader market reacted to a weaker-than-expected ADP payrolls report.

1 sept 2026, 19:46 UTC

Ocular Therapeutix Inc's shares are higher today, rebounding from earlier volatility and remaining well above the 20-day moving average.

31 ago 2026, 21:01 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, showing strength despite broader market pressure from hawkish Fed remarks. No specific news was identified.

28 ago 2026, 20:08 UTC

Ocular Therapeutix Inc shares are lower today, reflecting broader market declines amid rising U.S. Treasury yields and inflation concerns. No specific company news was identified.

27 ago 2026, 21:01 UTC

Ocular Therapeutix Inc shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

26 ago 2026, 19:36 UTC

Ocular Therapeutix Inc shares are lower today, with no specific news identified. This follows U.S. PCE data indicating inflationary pressures.

24 ago 2026, 20:06 UTC

Social Media

Ocular Therapeutix Inc. shares are lower amid a lawsuit from EyePoint, Inc. and broader market pressures, despite a brief rebound earlier in the session.

22 ago 2026, 00:02 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, maintaining momentum from Friday's close amid a broadly positive market performance.

21 ago 2026, 21:01 UTC

Ocular Therapeutix Inc shares are higher in after-market trading, reflecting strong performance amid positive sentiment in related sectors and developments in the cryptocurrency market.

20 ago 2026, 20:02 UTC

Ocular Therapeutix Inc is lower today amid broader market declines following Walmart's disappointing sales growth and guidance, contributing to increased selling pressure.

19 ago 2026, 23:21 UTC

Ocular Therapeutix Inc shows modest gains in after-market trading, with no specific news identified for the price movement. The stock remains above its 20-day moving average.

18 ago 2026, 22:26 UTC

Social Media

Ocular Therapeutix shares rise in after-market hours after Cowen set a $20 price target, and Baird raised its target to $30 amid competitive advantages.

17 ago 2026, 23:11 UTC

Ocular Therapeutix Inc's shares are higher in after-market trading, continuing a strong performance since Monday's close and reaching a notable high.

14 ago 2026, 19:46 UTC

Ocular Therapeutix Inc shares are lower amid a decline in the Pharmaceuticals sub-sector. The stock has traded down since Thursday's close.

13 ago 2026, 23:16 UTC

Ocular Therapeutix Inc's shares are lower in after-market hours, reflecting a slight decline since Thursday's close. No specific news was identified for this movement.

12 ago 2026, 20:01 UTC

Ocular Therapeutix Inc shares are higher in Wednesday's session, with elevated trading volume. The stock remains above its 20-day moving average.

11 ago 2026, 23:21 UTC

Ocular Therapeutix Inc shares fell during after-market hours, reaching a session low before slightly recovering. Broader market dynamics may be influencing this decline.

10 ago 2026, 20:06 UTC

Ocular Therapeutix Inc is trading higher, recovering above its 20-day moving average amid a broader trend of three consecutive sessions finishing higher.

7 ago 2026, 21:01 UTC

Ocular Therapeutix Inc shares are higher in after-market hours, continuing an upward trend after three consecutive sessions of gains.

6 ago 2026, 20:06 UTC

Ocular Therapeutix Inc shares are higher during Thursday's session, recovering from an earlier dip despite trading below their 20-day moving average.

Comparación entre iguales

Cambio de precio

Ocular Therapeutix Inc previsión

Precio Objetivo

By TipRanks

152.75% repunte

Estimación a 12 Meses

Media 25.25 USD  152.75%

Máximo 31 USD

Mínimo 18 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocular Therapeutix Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

9

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

320 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.